- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Kairos Pharma, LTD. - S-1, General form for registration of securities | - | SEC Filings | ||
| 21.01. | Kairos Pharma präsentiert Erfolge 2024 und Ziele für 2025 | - | Investing.com Deutsch | ||
| 21.01. | Kairos Pharma outlines 2024 achievements and 2025 goals | 1 | Investing.com | ||
| 14.01. | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.24 | Kairos Pharma Ltd.: Kairos Pharma to Participate in The Microcap Conference in January 2025 | 298 | ACCESS Newswire | LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025... ► Artikel lesen | |
| 13.12.24 | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| KAIROS PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.11.24 | Finanzvorstand von Kairos Pharma, Doug Samuelson, erwirbt Stammaktien im Wert von 3.750 US-Dollar | 3 | Investing.com Deutsch | ||
| 19.11.24 | Kairos Pharma approved to dual list on Upstream | 2 | Seeking Alpha | ||
| 19.11.24 | Kairos Pharma, Ltd.: Kairos Pharma Approved to Dual List on Upstream | 2 | GlobeNewswire (USA) | ||
| 19.11.24 | Kairos Pharma, LTD. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.24 | Kairos Pharma, LTD. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 22.10.24 | Kairos Pharma, Ltd.: Kairos Pharma to Present at the LD Micro Main Event XVII | 1 | GlobeNewswire (USA) | ||
| 09.10.24 | Kairos Pharma, Ltd.: Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 04.10.24 | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.09.24 | Kairos Pharma, LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.09.24 | Prevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd. | 285 | ACCESS Newswire | PHILADELPHIA, PA / ACCESSWIRE / September 25, 2024 / Prevail Partners LLC ("Prevail Partners") and Prevail InfoWorks Inc. ("Prevail InfoWorks") announce that they have entered into a strategic relationship... ► Artikel lesen | |
| 24.09.24 | Kairos Pharma, Ltd.: Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients | 1 | GlobeNewswire (USA) | ||
| 24.09.24 | Kairos Pharma, LTD. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09.24 | Kairos Pharma, Ltd.: Kairos Pharma Closing of $6.2 Million Initial Public Offering | 167 | GlobeNewswire (Europe) | LOS ANGELES, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. ("Kairos Pharma" or the "Company") (NYSE American: KAPA), a clinical stage biopharmaceutical company developing cancer therapeutics... ► Artikel lesen | |
| 17.09.24 | Kairos Pharma, LTD. - 8-K, Current Report | 2 | SEC Filings |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,19 | 0,00 % | Tempus AI's Options Frenzy: What You Need to Know | ||
| TECTONIC THERAPEUTIC | 54,73 | 0,00 % | Pre-market Movers: China Liberal Education, CARGO Therapeutics, Tectonic Therapeutic, Silexion Therapeutics, Banzai International | SANDY SPRINGS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,670 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million | Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366% vs. Q4 2023 and 41% vs. Q3 2024Preliminary unaudited product... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,690 | 0,00 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| CG ONCOLOGY | 30,150 | -0,30 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| CARGO THERAPEUTICS | 3,390 | 0,00 % | Safety Risk Sinks Cargo Therapeutics' Cancer Cell Therapy Prospect, Leading to 50% Staff Cut | ||
| 89BIO | 9,650 | +10,54 % | 89bio, Inc. - 8-K, Current Report | ||
| IMMUNOME | 10,510 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| QIAGEN | 42,995 | +0,22 % | Biotech Report: Evotec fest, Qiagen gehen leichter ins Wochenende | (shareribs.com) Frankfurt / New York 24.01.2025 - Biotech-Aktien tendieren am Freitag uneinheitlich. Für Qiagen geht es abwärts, während Evotec zulegen kann. An der Wall Street kann der Sektor zulegen.... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,290 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 22,320 | +3,14 % | Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? | ||
| AVIDITY BIOSCIENCES | 32,630 | +2,10 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,450 | -1,16 % | Vera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What Happened | ||
| STRUCTURE THERAPEUTICS | 30,310 | -1,43 % | Structure Therapeutics Inc.: Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer | SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,310 | +5,40 % | Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews |
KAIROS PHARMA LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,410 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAIROS PHARMA LTD finden Sie auf Wallstreet Online.
